CTSO CEO Phillip Chan Purchases Additional Shares

Phillip Chan, the Chief Executive Officer of CTSO, recently increased his stake in the company by purchasing 10,333 shares. The transaction took place on June 15, 2026, at an average price of $0.43 per share, amounting to a total value of $4,443.19. This move was not part of a pre-planned trading arrangement.

Insider Buying and Selling at Cytosorbents Corporation

Phillip Chan has been actively buying shares of CTSO. On June 12, 2026, he acquired 251,136 shares at $0.40 each. Previously, on November 18, 2025, he purchased 200,000 shares at $0.64 each. Meanwhile, Peter Mariani, the Chief Financial Officer, sold 10,548 shares at $1.09 each on August 19, 2025.

Other Institutional Activity in CTSO

Among CTSO's institutional investors, Avenir Corp reduced its position by 14,323 shares, ending with 5,215,776 shares valued at approximately $2,953,694. Vanguard Capital Management LLC significantly increased its holdings, adding 1,879,989 shares to reach a total of 1,879,989 shares worth $1,064,074. Skylands Capital, LLC cut its stake by 147,017 shares, holding 1,707,498 shares valued at $966,956. Neuberger Berman Group LLC grew its position by 57,367 shares, totaling 1,683,007 shares worth about $950,776. BlackRock, Inc. also added 12,441 shares, bringing its total to 782,992 shares, valued at $443,408.

CTSO Stock Snapshot

Shares of CTSO traded around $0.40. The stock has experienced various institutional activities and insider transactions, reflecting ongoing interest and adjustments by stakeholders.

Analysts Set New Price Targets

On January 12, 2026, D. Boral Capital maintained its 'buy' rating for CTSO, setting a price target of $10. HC Wainwright & Co. maintained a 'hold' rating with a $0.75 target on November 14, 2025. The consensus among analysts reflects a mixed outlook, with a recommendation key leaning towards 'hold' and a mean target price indicating moderate expectations.

About CTSO

CTSO is a company involved in the medical technology sector, focusing on developing and commercializing innovative therapies to treat life-threatening conditions. The company is headquartered in the United States and is led by CEO Phillip Chan.

Bottom Line

Phillip Chan's recent purchase of CTSO shares highlights his ongoing commitment to the company. While insider buying can signal confidence in the company's prospects, it's important to remember that these transactions are not always indicative of future performance. Investors and analysts continue to monitor CTSO's developments closely.